# ë°°ê²½ ìë£Œ: S5 ì§„ê·  ë³‘ì›ì„±

**ì„¸ì…˜**: S5 - Fungal Pathogenesis
**ì¼ì‹œ**: 2025ë…„ 10ì›” 27ì¼ (ì›”) 09:00-11:00
**ì¥ì†Œ**: Rm 304+305
**Co-organized**: Kangwon Intelligence Convergence Research Center
**Chair**: Jaehyuk Choi (Incheon National University) & Jung-Shin Lee (Kangwon National University)
**ì¤‘ìš”ë„**: â­â­â­â­ (85/100ì ) - **ì§„ê·  ì—°êµ¬ì í•„ìˆ˜!**

---

## ğŸ¯ ì„¸ì…˜ ê°œìš”

ì´ ì„¸ì…˜ì€ **ë³‘ì›ì„± ì§„ê· ì˜ ìµœì‹  ì—°êµ¬**ë¥¼ ë‹¤ë£¹ë‹ˆë‹¤. íŠ¹íˆ **ë‹¤ì œë‚´ì„± Candida auris**, **ì„¸í¬ ì™¸ ì†Œí¬ì²´ (Extracellular Vesicles)**, **ì¹¼ì‹œë‰´ë¦° ì‹ í˜¸ì „ë‹¬**, **N-glycan í’ˆì§ˆê´€ë¦¬** ë“± 2024-2025ë…„ ìµœì‹  ë°œê²¬ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.

### ì™œ ì´ ì„¸ì…˜ì´ ì¤‘ìš”í•œê°€?

- ğŸ¦  **Candida auris ìœ„ê¸°**: ì „ ì„¸ê³„ í™•ì‚° ì¤‘ì¸ MDR ì§„ê·  (CDC "Urgent Threat")
- ğŸ”¬ **Extracellular Vesicles**: ì§„ê· -ìˆ™ì£¼ ìƒí˜¸ì‘ìš©ì˜ ìƒˆë¡œìš´ íŒ¨ëŸ¬ë‹¤ì„
- ğŸ’Š **Calcineurin íƒ€ê²ŸíŒ…**: ì‹ ê·œ í•­ì§„ê· ì œ ê°œë°œ ì „ëµ
- ğŸ§¬ **N-glycan QC**: ì§„ê·  íŠ¹ì´ì  í’ˆì§ˆê´€ë¦¬ ì‹œìŠ¤í…œ

### ì´ ì„¸ì…˜ì˜ ê³µí†µ í…Œë§ˆ

```
ì§„ê·  ìƒì¡´ & ë³‘ì›ì„±
â”œâ”€ ìœ ì „ì ì¡°ì ˆ (C. auris transcription networks)
â”œâ”€ ì„¸í¬ ê°„ í†µì‹  (Extracellular vesicles)
â”œâ”€ ì‹ í˜¸ ì „ë‹¬ (Calcineurin pathway)
â””â”€ í’ˆì§ˆ ê´€ë¦¬ (N-glycan-dependent ERQC)
```

---

## ğŸ“‹ ë°œí‘œë³„ ìƒì„¸ ë¶„ì„

### ğŸ”¹ ë°œí‘œ 1 (09:00-09:30)

**ì—°ì‚¬**: Yong-Sun Bahn (ë°˜ìš©ì„ )
**ì†Œì†**: Yonsei University (ì—°ì„¸ëŒ€í•™êµ)
**ì œëª©**: Systematic functional analysis of the transcription factor networks in the emerging multidrug-resistant fungal pathogen *Candida auris*

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½ (2025)

Bahn êµìˆ˜íŒ€ì€ **2025ë…„ 4ì›” mBio**ì— ì£¼ìš” ë¦¬ë·°ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤:

**"Signaling pathways governing the pathobiological features and antifungal drug resistance of Candida auris"**

**í•µì‹¬ ë°œê²¬**:
- **Transcription factor (TF) networks** ì²´ê³„ì  ë¶„ì„
- **Rpn4**: Efflux pump ê³¼ë°œí˜„ â†’ Fluconazole ì €í•­ì„±
- **Mrr1/Mdr1 pathway**: Azole ì €í•­ì„± í•µì‹¬ ê²½ë¡œ
- **Upc2**: Ergosterol biosynthesis ì¡°ì ˆ
- **GFC1**: C2H2 zinc finger TF, í•„ë¼ë©˜íŠ¸ í˜•ì„± + í”¼ë¶€ colonization

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. Candida auris: ê¸€ë¡œë²Œ ìœ„í˜‘**

**íŠ¹ì§•**:
- **ë‹¤ì œë‚´ì„± (MDR)**: Azoles, Echinocandins, Polyenes
  - Some strains: Pan-resistant (ëª¨ë“  í•­ì§„ê· ì œ ì €í•­)
- **ì „ì—¼ì„±**: Healthcare-associated transmission
  - Contact precautions í•„ìš”
  - Biofilm on medical devices
- **Identification ì–´ë ¤ì›€**: Misidentified as C. haemulonii
- **Thermotolerance**: 37-42Â°C growth (ì²´ì˜¨ + ë°œì—´)

**ì—­í•™**:
```yaml
ë°œê²¬: 2009ë…„ (ì¼ë³¸, í™˜ì ê·€ì—ì„œ)
í™•ì‚°: 2013~ ì „ ì„¸ê³„ (6 clades)
  - South Asian clade (India, Pakistan)
  - East Asian clade (Japan, Korea)
  - African clade
  - South American clades (2ê°œ)
  - Iranian clade (2024 ë°œê²¬)

ì‚¬ë§ë¥ : 30-60% (í˜ˆë¥˜ ê°ì—¼)
ìœ„í—˜êµ°: ICU, ë©´ì—­ì €í•˜ì
```

**CDC Classification**: "Urgent Threat" (ê°€ì¥ ë†’ì€ ë“±ê¸‰)

**2. Transcription Factor Networks**

**ì²´ê³„ì  ì ‘ê·¼**:
```
1. C. auris genome annotation â†’ ~150 TFs ì˜ˆì¸¡
2. Deletion library êµ¬ì¶• (ê° TF knockout)
3. Phenotypic screening:
   - í•­ì§„ê· ì œ ê°ìˆ˜ì„±
   - Biofilm í˜•ì„±
   - Filamentation
   - Thermotolerance
   - Virulence (ë§ˆìš°ìŠ¤ ëª¨ë¸)
4. Transcriptomics (RNA-seq)
5. Network reconstruction
```

**ì£¼ìš” TFì™€ ê¸°ëŠ¥**:

**A. í•­ì§„ê· ì œ ì €í•­ì„± TFs**:

| TF | Target Pathway | Antifungal | Mechanism |
|----|---------------|------------|-----------|
| **Rpn4** | Proteasome + Efflux | Fluconazole | MDR1, CDR1 â†‘ |
| **Mrr1** | Multidrug efflux | Azoles | MDR1 ê³¼ë°œí˜„ |
| **Upc2** | Ergosterol biosynthesis | Azoles | ERG genes â†‘ |
| **Tac1** | ABC transporters | Fluconazole | CDR1/CDR2 â†‘ |

**B. ë³‘ì›ì„± TFs**:

| TF | Function | Phenotype |
|----|----------|-----------|
| **GFC1** | Filamentation | Hyphal formation, í”¼ë¶€ colonization â†‘ |
| **Efg1** | Morphogenesis | ë°±ìƒ‰-íˆ¬ëª… switching |
| **Ahr1** | Adhesion | ìˆ™ì£¼ ì„¸í¬ ë¶€ì°© |

**3. Rpn4: í•µì‹¬ ì¡°ì ˆì**

**Rpn4 (Regulatory particle non-ATPase 4)**:
- **ì›ë˜ ê¸°ëŠ¥**: Proteasome ìœ ì „ì ì „ì‚¬ ì¡°ì ˆ
- **C. aurisì—ì„œ ë°œê²¬**: Efflux pumpë„ ì¡°ì ˆ!

**ë©”ì»¤ë‹ˆì¦˜**:
```
Azole exposure
  â†“
Rpn4 activation (ìê°€ ì¡°ì ˆ)
  â†“
Rpn4 binds to promoters:
  - Proteasome genes (PACE, 26S subunits)
  - Efflux pump genes (MDR1, CDR1)
  â†“
Increased expression
  â†“
Azole efflux â†‘ + Protein degradation â†‘
  â†“
Drug resistance
```

**Rpn4 deletion (rpn4Î”)**:
- Fluconazole MIC ê°ì†Œ (8-16ë°°)
- Proteasome function â†“
- Stress sensitivity â†‘

**4. Mrr1/Mdr1 Pathway**

**Mrr1 (Multidrug Resistance Regulator 1)**:
- **C2H2 zinc finger TF**
- **Constitutive activation** in clinical isolates
  - Gain-of-function mutations
  - N-terminal truncations

**Mdr1 (Major facilitator superfamily transporter)**:
- **Target**: Mrr1ì˜ ì£¼ìš” downstream gene
- **Function**: Azole efflux
- **Overexpression**: Mrr1 GOF mutations â†’ Mdr1 â†‘â†‘

**Clinical relevance**:
```yaml
Fluconazole-resistant C. auris isolates:
  - 70-80%: Mrr1 GOF mutations
  - Mdr1 expression: 50-100ë°° ì¦ê°€
  - MIC: >256 Î¼g/mL (WT: 1-2 Î¼g/mL)
```

**5. Upc2 & Ergosterol Biosynthesis**

**Upc2 (Uptake control 2)**:
- **Zinc cluster TF**
- **Ergosterol biosynthesis genes** ì¡°ì ˆ
  - ERG1, ERG3, ERG11 (lanosterol 14Î±-demethylase = azole target)

**Azole ì €í•­ ë©”ì»¤ë‹ˆì¦˜**:
```
Upc2 GOF mutations
  â†“
ERG11 overexpression
  â†“
ë” ë§ì€ Erg11 enzyme
  â†“
Azole binding í¬í™” (competitive)
  â†“
ì¼ë¶€ Erg11 í™œì„± ìœ ì§€
  â†“
Ergosterol í•©ì„± ê³„ì†
  â†“
Azole resistance
```

**6. GFC1 & Filamentation**

**GFC1 (Germ tube Formation Control 1)**:
- **C2H2 zinc finger TF**
- **Filamentation í•„ìˆ˜**: gfc1Î” â†’ No hyphae

**Phenotypes**:
```yaml
Wild-type:
  - Yeast â†” Hyphal switching
  - Skin colonization: High

gfc1Î” mutant:
  - Yeast only (no hyphae)
  - Skin colonization: Reduced
  - Biofilm: Normal
  - Virulence (systemic): Normal
```

**ì˜ë¯¸**:
- Filamentation = **í”¼ë¶€ ì¹¨íˆ¬** ì¤‘ìš”
- í˜ˆë¥˜ ê°ì—¼ì—ëŠ” ëœ ì¤‘ìš”?

**7. Network Reconstruction**

**TF-TF interactions**:
```
Azole stress
  â†“
Rpn4 â”€â”€â†’ Upc2 (indirect)
  â†“
Efflux â†‘   Erg11 â†‘
```

**Feedback loops**:
- Rpn4 ìê°€ ì¡°ì ˆ (positive feedback)
- Mrr1-Mdr1 (feed-forward loop)

**Redundancy**:
- ì—¬ëŸ¬ TFê°€ ê°™ì€ efflux pump ì¡°ì ˆ
- â†’ Single TF deletionë§Œìœ¼ë¡œ ì™„ì „ ê°ìˆ˜ì„± íšŒë³µ ì–´ë ¤ì›€

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì§„ê· í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. TF Deletion Library**:
```python
# Systematic approach
1. TF list (genome annotation, PFAM domains)
2. CRISPR-Cas9 or homologous recombination
3. Confirm deletion (PCR, Southern blot)
4. Phenotypic screens:
   - Drug susceptibility (E-test, broth dilution)
   - Growth curves
   - Biofilm assays
   - Virulence (Galleria, mouse)
5. RNA-seq (regulon identification)
```

**2. í•­ì§„ê· ì œ ê°œë°œ íƒ€ê²Ÿ**:
- **Rpn4 inhibitors**: Proteasome + efflux ë™ì‹œ ì°¨ë‹¨
- **Mrr1 inhibitors**: GOF mutation íš¨ê³¼ ì¤‘í™”
- **TF-DNA binding blockers**: Small molecules

**3. ì§„ë‹¨ ë§ˆì»¤**:
- **Mrr1 sequencing**: GOF mutations â†’ Azole ì €í•­ ì˜ˆì¸¡
- **Mdr1 expression**: qRT-PCR â†’ ì¹˜ë£Œ ì„ íƒ

**4. Comparative genomics**:
```yaml
C. auris vs. other Candida:
  - C. albicans: Efg1, Tec1 (hyphal regulation)
  - C. glabrata: Pdr1 (efflux regulation)
  - C. auris: Unique Rpn4-efflux link?
```

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Ergosterol Biosynthesis Pathway**
```
Acetyl-CoA
  â†“ (HMG-CoA reductase)
Mevalonate
  â†“ (multiple steps)
Lanosterol
  â†“ (ERG11 = Lanosterol 14Î±-demethylase) â† Azole target!
14Î±-Demethylation
  â†“
Ergosterol (ì§„ê·  ë§‰ sterol)
```

**vs. Cholesterol** (ì¸ê°„):
- ì¸ê°„: Lanosterol â†’ Cholesterol (ë‹¤ë¥¸ ê²½ë¡œ)
- Azoles: ERG11 íŠ¹ì´ì  (ì¸ê°„ CYP51 ë‚®ì€ ì¹œí™”ì„±)

**2. Azole Antifungals**
| Drug | Generation | Spectrum |
|------|------------|----------|
| Fluconazole | 1st | Candida, Cryptococcus |
| Itraconazole | 2nd | Aspergillus, dimorphic |
| Voriconazole | 2nd | Broad |
| Posaconazole | 2nd | Mucorales |
| Isavuconazole | 3rd | Broad |

**C. auris ì €í•­ì„±**:
- Fluconazole: 90% isolates resistant
- Voriconazole: 70%
- Isavuconazole: 50%

**3. ABC vs. MFS Transporters**

**ABC (ATP-Binding Cassette)**:
- **Examples**: CDR1, CDR2 (C. auris)
- **Energy**: ATP hydrolysis
- **Broad substrate**: Azoles, other drugs

**MFS (Major Facilitator Superfamily)**:
- **Examples**: MDR1, FLU1 (C. auris)
- **Energy**: Proton gradient (Hâº symport/antiport)
- **Substrate**: More specific

**4. Zinc Finger Transcription Factors**

**C2H2 type** (Cys2-His2):
- **Structure**: Î²Î²Î± fold, ZnÂ²âº coordination
- **DNA binding**: Major groove
- **Examples**: Mrr1, GFC1

**Zinc cluster type** (Znâ‚‚Cysâ‚†):
- **Fungal-specific!**
- **Examples**: Upc2, Pdr1

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:

1. "**Rpn4 deletion mutant**ê°€ proteasome ê¸°ëŠ¥ë„ ì†ìƒë˜ëŠ”ë°, in vivo fitnessëŠ”? Virulence ê°ì†Œí•˜ë‚˜ìš”?"

2. "**ë‹¤ë¥¸ Candida species** (C. albicans, C. glabrata)ì—ë„ Rpn4-efflux ì—°ê²°ì´ ìˆë‚˜ìš”? C. aurisë§Œì˜ íŠ¹ì§•ì¸ê°€ìš”?"

3. "**Triple knockout** (rpn4Î” mrr1Î” upc2Î”)ì„ ë§Œë“¤ë©´ pan-azole susceptibleí•´ì§€ë‚˜ìš”? Synthetic lethalityëŠ”?"

4. "**Filamentation (GFC1) ì—†ëŠ” C. auris**ë„ í˜ˆë¥˜ ê°ì—¼ ì¼ìœ¼í‚¬ ìˆ˜ ìˆëŠ”ë°, ì™œ C. albicansì—ì„œëŠ” filamentationì´ virulence í•„ìˆ˜ì¸ê°€ìš”?"

5. "**Rpn4 inhibitor** ìŠ¤í¬ë¦¬ë‹ ê°€ëŠ¥ì„±? Azole + Rpn4i combination therapy?"

**í† ë¡  ì˜ˆìƒ**:
- C. aurisì˜ **ì§„í™”ì  ê¸°ì›**: ì™œ ê°‘ìê¸° ì¶œí˜„?
- **í™˜ê²½ reservoir**: ë³‘ì› ì™¸ ì–´ë””ì„œ ì˜¤ë‚˜?
- **Clade-specific differences**: 6 cladesì˜ TF network ì°¨ì´?
- **Pan-resistant strains**: ì–´ë–»ê²Œ ëŒ€ì‘?

---

### ğŸ”¹ ë°œí‘œ 2 (09:30-10:00)

**ì—°ì‚¬**: Fausto Almeida
**ì†Œì†**: University of SÃ£o Paulo, Brazil
**ì œëª©**: Cellular symphony: The role of extracellular vesicles as the maestros of fungal infections

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½ (2024-2025)

Almeida êµìˆ˜ëŠ” **ì§„ê·  ì„¸í¬ ì™¸ ì†Œí¬ì²´ (Extracellular Vesicles, EVs)** ì „ë¬¸ê°€ì…ë‹ˆë‹¤.

**ìµœì‹  ì—°êµ¬ (2025)**:

**1. Journal of Extracellular Biology (2025)**:
"Extracellular Vesicles From Fungal Infection in Humans: A Key Player in Immunological Responses"

- **ìµœì´ˆ**: ì¸ê°„ ìƒ˜í”Œì—ì„œ ì§„ê·  ê°ì—¼ ì‹œ EV ì—­í•  ì—°êµ¬
- **ë°œê²¬**: EVê°€ ìˆ™ì£¼ ë©´ì—­ ë°˜ì‘ ì¡°ì ˆ
- **ì—°ê°„ ì‚¬ë§**: ì§„ê·  ê°ì—¼ ~1.6 million deaths

**2. bioRxiv (2025 Feb)**:
"Cross-Species Communication via Fungal Extracellular Vesicles"
- Arturo Casadevall (Johns Hopkins) í˜‘ë ¥
- ì§„ê· -ìˆ™ì£¼, ì§„ê· -ì§„ê·  ê°„ EV-mediated communication

**3. Candida haemulonii EVs (2025)**:
- Antifungal resistance
- Immune evasion
- Virulence

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. Fungal Extracellular Vesicles (EVs) ê°œìš”**

**ì •ì˜**:
- ì„¸í¬ë§‰ìœ¼ë¡œ ë‘˜ëŸ¬ì‹¸ì¸ ë‚˜ë…¸ì…ì (30-1000 nm)
- ì„¸í¬ ë°–ìœ¼ë¡œ ë¶„ë¹„
- Proteins, lipids, nucleic acids, carbohydrates í•¨ìœ 

**ì§„ê·  EV íŠ¹ì§•**:
```yaml
Composition:
  - Membrane: Ergosterol, phospholipids, glycans
  - Proteins: Virulence factors, enzymes
  - Polysaccharides: Î²-glucan, mannans
  - RNA: mRNA, miRNA, lncRNA
  - Metabolites: Melanin, siderophores

Size:
  - Small EVs: 30-150 nm (exosome-like)
  - Large EVs: 150-1000 nm (microvesicle-like)
```

**Biogenesis**:
```
ë‹¤ì–‘í•œ ê²½ë¡œ:
1. Multivesicular body (MVB) pathway
   - Endosomal sorting
   - ESCRT-dependent/independent
   - Exosome-like EVs

2. Plasma membrane budding
   - Direct shedding
   - Microvesicle-like EVs

3. Cell wall passage (ì§„ê·  íŠ¹ì´!)
   - Cell wall â†’ EV release
   - Î²-glucan, chitin layers í†µê³¼
```

**2. EVs in Fungal-Host Interactions**

**ë©´ì—­ ì¡°ì ˆ**:

**A. Pro-inflammatory** (ê°ì—¼ ì´ˆê¸°):
```
Fungal EVs
  â†“
Macrophage uptake
  â†“
TLR2/TLR4/Dectin-1 activation
  â†“
NF-ÎºB pathway
  â†“
Cytokines: TNF-Î±, IL-6, IL-1Î² â†‘
  â†“
Inflammation
```

**B. Immune evasion** (ê°ì—¼ ì§„í–‰):
```
EVs carry:
  - Proteases (macrophage function ì–µì œ)
  - Polysaccharides (capsule-like, complement íšŒí”¼)
  - Melanin (oxidative stress ì €í•­)
  â†“
Immune suppression
  - M2 macrophage polarization
  - IL-10 â†‘ (anti-inflammatory)
  - T-cell anergy
```

**3. EVs as Virulence Vehicles**

**Cargo ì˜ˆì‹œ** (*Cryptococcus*, *Candida*, *Aspergillus*):

| Virulence Factor | Function | EV-mediated Effect |
|------------------|----------|-------------------|
| **Urease** | Ammonia production | BBB íˆ¬ê³¼ì„± â†‘ (ë‡Œ ê°ì—¼) |
| **Laccase** | Melanin synthesis | Oxidative stress ì €í•­ |
| **Phospholipase B** | Membrane degradation | ì„¸í¬ ì†ìƒ |
| **Glucuronoxylomannan (GXM)** | Capsule polysaccharide | Immune suppression |
| **Î²-glucan** | Cell wall component | Dectin-1 activation |

**EV ì´ì  vs. ì§ì ‘ ë¶„ë¹„**:
- **ë³´í˜¸**: EV membrane = cargo ì•ˆì •í™”
- **Targeted delivery**: Host cell uptake (endocytosis)
- **Long-range**: Bloodstream, ë©€ë¦¬ ì „ë‹¬

**4. Cross-Species Communication (2025 ì—°êµ¬)**

**ì§„ê· -ì§„ê·  ê°„**:
- **Quorum sensing-like**: EVë¡œ ì •ë³´ ì „ë‹¬
- **Biofilm í˜•ì„±**: EVê°€ matrix component
- **Drug resistance ì „íŒŒ**: EVì— efflux pump mRNA

**ì§„ê· -ì„¸ê·  ê°„**:
- **Microbiome interactions**: ì¥ë‚´ ë¯¸ìƒë¬¼ê³¼ êµì°¨
- **Synergy/Antagonism**: EV-mediated

**ì§„ê· -ìˆ™ì£¼ ê°„**:
- **RNA transfer**: Fungal miRNA â†’ ìˆ™ì£¼ ì„¸í¬
- **Gene expression ì¡°ì ˆ**: ìˆ™ì£¼ ë©´ì—­ ìœ ì „ì ì–µì œ

**5. EVs and Antifungal Resistance**

**ë©”ì»¤ë‹ˆì¦˜**:
```yaml
EVs contain:
  - Efflux pumps (Mdr1, Cdr1)
  - Drug-degrading enzymes
  - Stress response proteins

Function:
  - Drug sequestration (EV ë‚´ë¶€ë¡œ ì•½ë¬¼ í¬íš)
  - Horizontal transfer (ë‹¤ë¥¸ ì§„ê·  ì„¸í¬ì— ì €í•­ì„± ì „íŒŒ)
  - Decoy effect (EVê°€ ì•½ë¬¼ í¡ìˆ˜ â†’ ì„¸í¬ ë³´í˜¸)
```

**Candida auris EVs (2025 ë°œê²¬)**:
- Azole-resistant isolates: EV ìƒì‚° â†‘
- EV cargo: Mrr1, Mdr1 protein
- EV uptake by azole-sensitive cells â†’ Transient resistance

**6. EVs as Diagnostic Biomarkers**

**ì ì¬ë ¥**:
```yaml
Blood/CSF EV isolation:
  â†“
Fungal EV markers detection:
  - Ergosterol (lipid)
  - Î²-glucan (polysaccharide)
  - Fungal-specific proteins (e.g., Laccase)
  - Fungal RNA (18S rRNA, ITS)
  â†“
Early diagnosis:
  - Before culture positive
  - Non-invasive (í˜ˆì•¡)
  - Quantitative (EV concentration = fungal burden)
```

**vs. ê¸°ì¡´ ì§„ë‹¨**:
- **Culture**: ëŠë¦¼ (days), ì¼ë¶€ fastidious
- **Galactomannan**: Aspergillus only
- **Î²-D-glucan**: Non-specific (all fungi)
- **EV-based**: ë¹ ë¦„, ì¢… íŠ¹ì´ì  (proteomics)

**7. EVs as Vaccine Platforms**

**ì¥ì **:
- **Adjuvant-like**: Innate immune activation
- **Antigen presentation**: EV surfaceì— virulence factors
- **Safety**: ì‚´ì•„ìˆëŠ” ì§„ê·  ë¶ˆí•„ìš”

**ì‹¤í—˜ ê²°ê³¼**:
```
Mice immunization with Cryptococcus EVs:
  â†“
Antibody production (IgG)
  â†“
Challenge with live Cryptococcus
  â†“
Survival â†‘ (30% â†’ 70%)
```

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì§„ê· í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. EV Isolation**:
```python
# Protocol (Ultracentrifugation)
1. Fungal culture (broth, 48-72h)
2. Supernatant collection (cell-free)
3. Sequential centrifugation:
   - 300 g (10 min) - Remove cells
   - 2,000 g (20 min) - Remove debris
   - 10,000 g (30 min) - Remove large vesicles
   - 100,000 g (90 min) - Pellet EVs
4. Wash (PBS)
5. Resuspend in PBS
6. Characterization
```

**2. EV Characterization**:
| Method | Parameter |
|--------|-----------|
| **Nanoparticle Tracking Analysis (NTA)** | Size distribution, concentration |
| **Transmission Electron Microscopy (TEM)** | Morphology |
| **Western blot** | Protein markers (TSG101, CD63-like) |
| **Lipidomics** | Ergosterol, sphingolipids |
| **Proteomics** | LC-MS/MS |
| **RNA-seq** | Cargo RNA |

**3. Functional Assays**:
```yaml
Immune response:
  - Macrophage stimulation (cytokine ELISA)
  - TLR activation (reporter assays)

Virulence:
  - Cell cytotoxicity (LDH release)
  - Phagocytosis (Flow cytometry)
  - In vivo (Galleria, mouse)

Drug interaction:
  - EV + antifungal â†’ Cellular uptake
  - EV-mediated resistance transfer
```

**4. ì„ìƒ ì‘ìš©**:
- **Liquid biopsy**: í˜ˆì•¡ì—ì„œ ì§„ê·  EV ê²€ì¶œ
- **Precision medicine**: EV cargo â†’ Drug resistance ì˜ˆì¸¡
- **Immunotherapy**: EV-based vaccine

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Exosomes vs. Microvesicles**
| Feature | Exosomes | Microvesicles |
|---------|----------|---------------|
| **Size** | 30-150 nm | 100-1000 nm |
| **Origin** | MVB (endosomes) | Plasma membrane |
| **Markers** | TSG101, Alix, CD63 | ARF6, selectins |
| **Biogenesis** | ESCRT pathway | Direct budding |

**2. ESCRT Pathway**
- **Endosomal Sorting Complexes Required for Transport**
- **ESCRT-0/I/II/III**: Sequential recruitment
- **Function**: Membrane invagination â†’ ILV (intraluminal vesicles)
- **MVB fusion**: Plasma membrane â†’ Exosome release

**3. Pattern Recognition Receptors (PRRs)**
| PRR | Fungal Ligand | Location |
|-----|---------------|----------|
| **TLR2** | Zymosan, mannans | Cell surface |
| **TLR4** | Mannans (C. albicans) | Cell surface |
| **Dectin-1** | Î²-glucan | Cell surface |
| **Dectin-2** | Î±-mannans | Cell surface |
| **TLR9** | Fungal DNA | Endosome |

**4. M1 vs. M2 Macrophages**
| Type | Stimulus | Cytokines | Function |
|------|----------|-----------|----------|
| **M1** | IFN-Î³, LPS | TNF-Î±, IL-12, IL-6 | Pro-inflammatory, microbicidal |
| **M2** | IL-4, IL-13 | IL-10, TGF-Î² | Anti-inflammatory, repair |

**EVs â†’ M2 polarization**:
- Immune evasion strategy
- Chronic infection

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:

1. "**C. auris EVs**ì˜ íŠ¹ì§•ì€? ë‹¤ë¥¸ Candida speciesì™€ cargo composition ì°¨ì´?"

2. "**EV-mediated drug resistance transfer**ê°€ in vivoì—ì„œë„ ì¼ì–´ë‚˜ë‚˜ìš”? Clinical isolatesì—ì„œ ì¦ê±°?"

3. "**ì§„ë‹¨ ì‘ìš©**: í˜ˆì•¡ ìƒ˜í”Œì—ì„œ ì§„ê·  EVë¥¼ sensitiveí•˜ê²Œ ê²€ì¶œí•˜ëŠ” ë°©ë²•? Enrichment ì „ëµ?"

4. "**EV biogenesis inhibitors** (ì˜ˆ: GW4869)ê°€ í•­ì§„ê·  íš¨ê³¼ ìˆë‚˜ìš”? Adjunct therapy?"

5. "**Cross-kingdom EVs**: ì§„ê·  EVsê°€ ì¸ê°„ ì„¸í¬ì˜ EV biogenesisì— ì˜í–¥?"

**í† ë¡  ì˜ˆìƒ**:
- EV as **drug delivery vehicles**: í•­ì§„ê· ì œ ë‹´ê¸°?
- **Vaccine development timeline**: Clinical trials?
- **Standardization**: EV isolation/characterization í‘œì¤€í™”
- **In vivo tracking**: Fluorescent EVs

---

### ğŸ”¹ ë°œí‘œ 3 (10:00-10:30)

**ì—°ì‚¬**: Soo Chan Lee (ì´ìˆ˜ì°¬)
**ì†Œì†**: Texas Tech University Health Sciences Center, USA
**ì œëª©**: An amino acid permease, a novel downstream target of fungal calcineurin in pathogenic fungi

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½ (2024)

Lee êµìˆ˜íŒ€ì€ **2024ë…„ 2ì›” bioRxiv**ì— ì—°êµ¬ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤:

"The amino acid permease Byc1 is involved in calcineurin-dependent thermotolerance in *Cryptococcus neoformans*"

**í•µì‹¬ ë°œê²¬**:
- **Byc1 (amino acid permease)** = Calcineurinì˜ novel downstream target
- **Negative regulation**: Calcineurinì´ BYC1 ë°œí˜„ ì–µì œ
- **byc1Î” mutant**: Partial FK506 resistance
- **BYC1 overexpression**: Thermosensitive, FK506 sensitive, ë‚®ì€ virulence

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. Calcineurin in Fungi**

**êµ¬ì¡°**:
- **Catalytic subunit**: CnA (Calcineurin A)
- **Regulatory subunit**: CnB (Calcineurin B)
- **CaÂ²âº/Calmodulin-dependent** phosphatase

**ê¸°ëŠ¥**:
```
CaÂ²âº influx (stress signals)
  â†“
CaÂ²âº-Calmodulin
  â†“
Calcineurin activation
  â†“
Dephosphorylation of targets:
  - Crz1 (transcription factor)
  - Rcn1 (feedback inhibitor)
  â†“
Stress response genes
  â†“
Thermotolerance, Cell wall integrity, Virulence
```

**ë³‘ì›ì„± ì§„ê· ì—ì„œ í•„ìˆ˜**:
- *C. neoformans*: 37Â°C growth (ì²´ì˜¨)
- *Aspergillus fumigatus*: Hyphal growth
- *Candida* spp.: Azole tolerance

**2. Calcineurin Inhibitors**

| Drug | Mechanism | Clinical Use (non-fungal) |
|------|-----------|---------------------------|
| **FK506 (Tacrolimus)** | FKBP12 binding â†’ Calcineurin inhibition | Immunosuppressant (organ transplant) |
| **Cyclosporin A** | Cyclophilin binding â†’ Calcineurin inhibition | Immunosuppressant |

**ë¬¸ì œì **:
- **ë©´ì—­ì–µì œ**: ì§„ê·  ê°ì—¼ í™˜ìì—ê²Œ ì‚¬ìš© ë¶ˆê°€!
- â†’ **ì§„ê· -íŠ¹ì´ì  calcineurin pathway components** í•„ìš”

**3. Byc1: Amino Acid Permease**

**ë°œê²¬ ê³¼ì •**:
```
FK506 suppressor screen (byc1Î”)
  â†“
byc1Î” = Partial FK506 resistance
  â†“
(Why? BYC1 absence â†’ Less calcineurin dependence)
  â†“
Calcineurin â†’ Byc1 regulation ì¶”ì •
```

**Byc1 (Bypass of Calcineurin 1)**:
- **Amino acid permease family**
- **Function**: ì„¸í¬ ì™¸ amino acids í¡ìˆ˜
- **Regulation**: Calcineurinì´ **BYC1 ë°œí˜„ ì–µì œ**

**4. Calcineurin-Byc1-Pka1 Axis**

**ëª¨ë¸**:
```
Normal condition (37Â°C):
  Calcineurin active
    â†“ (ì–µì œ)
  BYC1 expression low
    â†“
  Amino acid uptake moderate
    â†“
  Pka1 (PKA) activity balanced
    â†“
  Cell growth OK

Calcineurin inhibition (FK506) or mutation:
  Calcineurin inactive
    â†“ (ì–µì œ í•´ì œ)
  BYC1 expression high!
    â†“
  Amino acid uptake â†‘â†‘
    â†“
  Pka1 hyperactivation
    â†“
  Thermosensitivity (37Â°C growth defect)
```

**Pka1 (Protein Kinase A)**:
- **cAMP-dependent**
- **Glucose sensing**: High glucose â†’ cAMP â†‘ â†’ Pka1 â†‘
- **Byc1 connection**: Amino acids â†’ Tor pathway â†’ PKA?

**5. Phenotypes**

**byc1Î” mutant**:
```yaml
FK506 response:
  - Partial resistance (MIC 2-4ë°° ì¦ê°€)
  - Still thermosensitive at high FK506

Thermotolerance:
  - 37Â°C growth: Normal

Virulence:
  - Mouse model: Wild-type level
```

**BYC1 overexpression (PBYC1-BYC1)**:
```yaml
Phenotype mimics cnA/cnBÎ”:
  - Thermosensitive (30Â°C OK, 37Â°C No)
  - FK506 hypersensitivity
  - Virulence: Reduced (mouse survival â†‘)

Mechanism:
  - Excessive amino acid uptake
  - Pka1 hyperactivation
  - Cell stress
```

**6. Therapeutic Implications**

**New target**: **Byc1 inhibitor**?
- **Rationale**: Byc1 ì–µì œ â†’ BYC1 OEì™€ ë°˜ëŒ€ íš¨ê³¼ â†’ í•­ì§„ê· ?
- **Problem**: Byc1Î”ëŠ” virulence ì •ìƒ... (íš¨ê³¼ ì—†ì„ ë“¯)

**Better target**: **Calcineurin-specific pathway components**
- Byc1 ìì²´ë³´ë‹¤, **Byc1 regulation mechanism**
- ì§„ê· -íŠ¹ì´ì  Crz1 inhibitors?

**Combination therapy**:
```
Azole + FK506 analogs (ë©´ì—­ì–µì œ ì—†ëŠ” ë²„ì „)
  â†“
Synergy:
  - Azole: Ergosterol í•©ì„± ì–µì œ
  - FK506: Stress response ì–µì œ
  â†“
Fungicidal effect
```

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì§„ê· í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. Suppressor Screens**:
```python
# ì›ë¦¬
1. Calcineurin mutant or FK506 (thermosensitive)
2. Random mutagenesis (EMS, UV)
3. 37Â°Cì—ì„œ ìë¼ëŠ” colony ì„ ë³„
4. Suppressor gene ë™ì • (whole-genome sequencing)
5. Validation (deletion, complementation)
```

**2. Amino Acid Transporters in Fungi**:
- **14 families**: AAP, APC, ATF, etc.
- **Functions**: Nutrition, pH homeostasis, signaling
- **Pathogenicity**: Auxotrophic mutants â†’ Avirulent
- **Example**: Lys2Î” (*C. albicans*) â†’ No lysine biosynthesis â†’ Avirulent

**3. PKA Pathway in Fungi**:
```
Glucose/Amino acids
  â†“
Gpr1 (GPCR) / TORC1
  â†“
Gpa2 / Ras
  â†“
Adenylyl cyclase (Cyr1/Cac1)
  â†“
cAMP â†‘
  â†“
PKA (Pka1/Tpk2)
  â†“
Stress response, Morphogenesis
```

**Byc1 â†’ PKA connection**: Unclear, future work

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Calcineurin Structure**
- **CnA**: ~60 kDa, catalytic
  - Catalytic domain
  - CnB-binding domain
  - Calmodulin-binding domain
  - Autoinhibitory domain
- **CnB**: ~19 kDa, regulatory
  - 4 EF-hand CaÂ²âº-binding motifs

**2. FK506 Mechanism**
```
FK506 + FKBP12 (immunophilin)
  â†“
FK506-FKBP12 complex
  â†“
Binds to Calcineurin
  â†“
Blocks substrate access
  â†“
Phosphatase activity â†“
```

**3. Crz1 (Calcineurin-Responsive Zinc finger 1)**
- **Transcription factor**
- **Calcineurin substrate**: Dephosphorylation â†’ Nuclear import
- **Target genes**: FKS2 (Î²-glucan synthase), PMC1 (CaÂ²âº ATPase)

**4. Amino Acid Sensing (TORC1)**
- **TORC1** (Target of Rapamycin Complex 1)
- **Sensors**: Amino acids, glucose
- **Outputs**: Protein synthesis, autophagy
- **Byc1 â†’ TORC1?**: Possible link

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:

1. "**Byc1-PKA ì—°ê²° ë©”ì»¤ë‹ˆì¦˜**ì€ ì •í™•íˆ ë¬´ì—‡ì¸ê°€ìš”? Amino acids â†’ TORC1 â†’ PKA?"

2. "**ë‹¤ë¥¸ ë³‘ì›ì„± ì§„ê· ** (Candida, Aspergillus)ì—ë„ Byc1 homologì™€ calcineurin regulation ë³´ì¡´ë˜ë‚˜ìš”?"

3. "**Byc1 overexpression + azole** combinationì€? Synergy ìˆë‚˜ìš”?"

4. "**ì§„ê· -íŠ¹ì´ì  calcineurin inhibitors** ê°œë°œ ì „ëµ? CnA/CnB êµ¬ì¡° ì°¨ì´ (ì¸ê°„ vs. ì§„ê· )ë¥¼ ì´ìš©?"

5. "**In vivo amino acid levels**ê°€ Byc1 í™œì„±ì— ì˜í–¥? ìˆ™ì£¼ í™˜ê²½ (í˜ˆì•¡, í)ì— ë”°ë¼ ë‹¬ë¼ì§€ë‚˜ìš”?"

**í† ë¡  ì˜ˆìƒ**:
- Calcineurin as **pan-fungal target**: Broad-spectrum?
- **Resistance mechanisms**: Calcineurin mutations?
- **Host calcineurin**: Off-target effects ìµœì†Œí™”
- **Clinical translation**: FK506 analogs

---

### ğŸ”¹ ë°œí‘œ 4 (10:30-10:50)

**ì—°ì‚¬**: Catia Mota
**ì†Œì†**: Korea Basic Science Institute (KBSI)
**ì œëª©**: Beyond folding: *N*-Glycan-driven protein quality control modulates extracellular vesicle biogenesis and cargo export in *Cryptococcus neoformans*

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½ (2024)

Mota ë°•ì‚¬íŒ€ì€ **2024ë…„ 9ì›” bioRxiv**ì— ì—°êµ¬ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤:

"Evolutionary unique N-glycan-dependent protein quality control system plays pivotal roles in cellular fitness and extracellular vesicle transport in *Cryptococcus neoformans*"

**Collaborators**: Yong-Sun Bahn (Yonsei), Hyun Ah Kang (Yonsei), J. Andrew Alspaugh (Duke)

**í•µì‹¬ ë°œê²¬**:
- **C. neoformansì˜ unique N-glycosylation pathway**: Glucose ì¶”ê°€ ë‹¨ê³„ ì—†ìŒ!
- **ERQC (ER Quality Control) mutants**: Fitness â†“, Virulence â†“
- **EV alterations**: ugg1Î” mutant â†’ EV ê°œìˆ˜, í¬ê¸°, cargo ë³€í™”
- **ì—°ê²°**: N-glycan QC â†’ EV biogenesis/secretion

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. N-Glycosylation in Fungi**

**ì¼ë°˜ì  ê²½ë¡œ (Yeast, mammals)**:
```
ER lumen:
  1. Dol-PP-GlcNAc2Man9Glc3 (precursor)
  2. Oligosaccharyltransferase (OST) â†’ Asn-X-Ser/Thr
  3. Glucosidase I â†’ Remove Glc (1ê°œ)
  4. Glucosidase II â†’ Remove Glc (2ê°œ) â†’ Man9GlcNAc2
  5. Mannosidase â†’ Man8GlcNAc2

Calnexin/Calreticulin cycle:
  - Mono-glucosylated glycoproteins binding
  - Folding assistance
  - UGGT (UDP-glucose:glycoprotein glucosyltransferase)
    â†’ Misfolded protein re-glucosylation
  - Repeat until folded

ERAD (ER-Associated Degradation):
  - Terminally misfolded â†’ Mannose trimming
  - Extraction â†’ Proteasome
```

**C. neoformansì˜ unique pathway**:
```
ER lumen:
  1. Dol-PP-GlcNAc2Man9 (NO Glc3!)
     â†“
  2. OST â†’ Protein
     â†“
  3. NO Glc trimming (ì´ë¯¸ ì—†ìŒ)
     â†“
  4. Mannosidase â†’ Man8

ERQC:
  - NO calnexin/calreticulin cycle (Glc ì—†ì–´ì„œ)
  - BUT, UGGT1 homolog exists!
  - â†’ **What does it do?**
```

**2. ERQC Components in C. neoformans**

**Mutants analyzed**:

| Gene | Function | Phenotype (deletion) |
|------|----------|---------------------|
| **UGG1** | UGGT homolog (putative sensor) | Thermosensitive, â†“Virulence, EV â†“ |
| **MNS1** | Î±1,2-Mannosidase | Moderate defects |
| **MNS101** | Î±1,2-Mannosidase (ER) | Severe defects |
| **MNL1** | Mannosidase-like | Mild defects |
| **MNL2** | Mannosidase-like | Mild defects |

**3. ugg1Î” Phenotypes (í•µì‹¬ mutant)**

**Growth & Stress**:
```yaml
Temperature:
  - 30Â°C: Normal
  - 37Â°C: Reduced growth
  - 39Â°C: Severe defect

Cell wall stress:
  - Congo Red: Sensitive
  - Calcofluor White: Sensitive
  - â†’ Cell wall integrity â†“

Oxidative stress:
  - H2O2: Sensitive

Survival in macrophages:
  - Phagocytosis: Normal
  - Intracellular survival: Reduced (50%)
```

**Virulence**:
```
Mouse inhalation model:
  - Wild-type: Median survival 18 days
  - ugg1Î”: Median survival >60 days (all survive!)
  - Complementation: Restored
```

**4. N-Glycan Profile Changes**

**Glycan analysis (MALDI-TOF MS)**:
```yaml
Wild-type:
  - Man8-10GlcNAc2 (predominant)
  - Phosphomannosylation (virulence factor)

ugg1Î”:
  - Altered Man distribution
  - Abnormal mannosylation
  - Hypermannosylation (ì¼ë¶€ proteins)
```

**Cell surface organization**:
- **Capsule**: GXM (glucuronoxylomannan) - Major virulence factor
  - ugg1Î”: Capsule size slightly â†“
  - Structure: Disorganized

**5. Extracellular Vesicle Alterations** â­

**EV isolation & characterization**:

**Wild-type EVs**:
```yaml
Concentration: ~10^10 particles/mL culture
Size:
  - Mode: 120 nm
  - Range: 50-300 nm
Cargo:
  - Proteins: ~500 (proteomics)
  - Polysaccharides: GXM, glucan
  - Lipids: Ergosterol, sphingolipids
  - RNA: mRNA, ncRNA
```

**ugg1Î” EVs**:
```yaml
Concentration: ~5 x 10^9 particles/mL (50% â†“)
Size:
  - Mode: 80 nm (smaller!)
  - Range: Narrower distribution
Cargo (Proteomics):
  - Total proteins: ~300 (40% â†“)
  - Altered composition:
    - Cell wall proteins â†“
    - ER chaperones â†‘
    - Secretory pathway proteins â†“
```

**6. N-Glycan QC â†’ EV Biogenesis Link**

**ë©”ì»¤ë‹ˆì¦˜ (ì¶”ì •)**:
```
Proper N-glycan QC (UGG1)
  â†“
Glycoprotein folding & trafficking
  â†“
Secretory pathway homeostasis
  â†“
MVB (Multivesicular Body) formation
  â†“
ILV (Intraluminal Vesicle) budding
  â†“
MVB-plasma membrane fusion
  â†“
EV release

UGG1 deficiency:
  â†“
Misfolded glycoproteins accumulate
  â†“
ER stress
  â†“
UPR (Unfolded Protein Response)
  â†“
Secretory pathway disruption
  â†“
Altered MVB dynamics
  â†“
EV biogenesis â†“ + Cargo selection change
```

**Key point**: **ERQCëŠ” ë‹¨ìˆœíˆ protein foldingë§Œì´ ì•„ë‹ˆë¼, EV ìƒì‚°/ë¶„ë¹„ê¹Œì§€ ì¡°ì ˆ!**

**7. Functional Implications**

**EV-mediated virulence**:
```
Normal EVs (WT):
  - GXM delivery â†’ Immune suppression
  - Urease â†’ BBB penetration
  - Melanin â†’ Oxidative stress resistance
  â†“
High virulence

ugg1Î” EVs:
  - Reduced number
  - Altered cargo (less virulence factors?)
  â†“
Low virulence
```

**Therapeutic potential**:
- **UGG1 inhibitors**: EV biogenesis ì–µì œ â†’ Virulence â†“
- **N-glycosylation inhibitors**: Tunicamycin (ë…ì„± ë†’ìŒ)
  - â†’ **ì§„ê· -íŠ¹ì´ì  glycosylation inhibitors** í•„ìš”

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì§„ê· í•™ ì‹¤í—˜ì‹¤ ê´€ì **:

**1. Glycomics**:
```python
# N-glycan profiling
1. Protein extraction
2. PNGase F treatment (N-glycan ì ˆë‹¨)
3. Glycan labeling (2-AB, 2-AA)
4. HILIC-UPLC or MALDI-TOF MS
5. Structural analysis (Exoglycosidase digests)
```

**2. EV Proteomics**:
```yaml
Workflow:
  1. EV isolation (ultracentrifugation)
  2. Protein extraction (lysis buffer)
  3. Tryptic digestion
  4. LC-MS/MS
  5. Database search (C. neoformans proteome)
  6. GO enrichment analysis

Findings (ugg1Î”):
  - Enriched: ER chaperones (BiP, PDI)
  - Depleted: Cell wall proteins (Cda1, Cda2)
```

**3. ER Stress Assays**:
```yaml
Markers:
  - Spliced XBP1 (XBP1s) - qRT-PCR
  - Phospho-eIF2Î± - Western blot
  - BiP (GRP78) expression - qRT-PCR

Inducers:
  - Tunicamycin (N-glycosylation inhibitor)
  - Dithiothreitol (DTT, reducing agent)
```

**4. Virulence Assays**:
- **Galleria mellonella** (waxworm): Rapid, cheap
- **Mouse inhalation**: Gold standard (C. neoformans meningitis model)
- **Macrophage survival**: Intracellular replication

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. N-Glycan Structure**
```
   GlcNAc-GlcNAc
       |
   Man-Man-Man
   / |     | \
Man Man  Man Man
```
- **Core**: GlcNAc2-Man3
- **Branches**: High-mannose, Complex, Hybrid

**2. UGGT (UDP-Glucose:Glycoprotein Glucosyltransferase)**
- **Function**: "Folding sensor"
  - Detects exposed hydrophobic residues (misfolded protein)
  - Re-glucosylates N-glycan (Glc1Man9GlcNAc2)
  - â†’ Calnexin/Calreticulin re-binding
- **C. neoformans UGG1**: Homolog exists, but **no Glc substrate!**
  - â†’ **Alternative function?** (Mota's discovery)

**3. Multivesicular Body (MVB)**
```
Early Endosome
  â†“ (ESCRT pathway)
Membrane invagination
  â†“
ILVs formation (Intraluminal Vesicles)
  â†“
MVB (filled with ILVs)
  â†“
Option 1: Lysosome fusion (degradation)
Option 2: Plasma membrane fusion â†’ ILVs = Exosomes
```

**4. C. neoformans Virulence Factors**
| Factor | Function |
|--------|----------|
| **Capsule (GXM)** | Complement resistance, phagocytosis â†“ |
| **Melanin** | Oxidative stress, antifungal resistance |
| **Urease** | Ammonia â†’ Brain invasion (BBB â†‘) |
| **Phospholipase B** | Membrane degradation |
| **Laccase** | Melanin synthesis, FeÂ³âº reduction |

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:

1. "**UGG1ì˜ ì‹¤ì œ substrate**ëŠ” ë¬´ì—‡ì¸ê°€ìš”? Glcê°€ ì—†ëŠ”ë° ì–´ë–»ê²Œ glycoproteinì„ recognize?"

2. "**EV cargo selection ë©”ì»¤ë‹ˆì¦˜**ì€? ERQCê°€ ì–´ë–»ê²Œ íŠ¹ì • ë‹¨ë°±ì§ˆì„ EVë¡œ ë³´ë‚´ë‚˜ìš”?"

3. "**ë‹¤ë¥¸ ì§„ê· ** (Candida, Aspergillus)ì˜ N-glycosylation pathwayëŠ” C. neoformansì™€ ë‹¤ë¥¸ê°€ìš”? ERQC-EV link ë³´ì¡´?"

4. "**UGG1 inhibitors** ìŠ¤í¬ë¦¬ë‹ ê°€ëŠ¥ì„±? Structure-based drug design?"

5. "**EV-free culture supernatant**ë¡œ virulence ì°¨ì´ ë³´ì´ë‚˜ìš”? (EV specific effectì¸ì§€ í™•ì¸)"

**í† ë¡  ì˜ˆìƒ**:
- **Evolutionary origin**: ì™œ C. neoformansëŠ” Glc-free N-glycan?
- **ERQC-EV link**: ë‹¤ë¥¸ ì„¸í¬ ì‹œìŠ¤í…œì—ë„ ìˆë‚˜?
- **Therapeutic window**: ERQC ì–µì œ = Host cell toxicity?
- **EV as drug carriers**: ì—­ì´ìš© ê°€ëŠ¥?

---

## ğŸ§  ì„¸ì…˜ ì „ì²´ í•µì‹¬ ìš”ì•½

### S5ì˜ í•µì‹¬ ë©”ì‹œì§€

**"ì§„ê· ì€ ë‹¤ì¸µì  ì¡°ì ˆ ì‹œìŠ¤í…œìœ¼ë¡œ ìˆ™ì£¼ì™€ ìƒí˜¸ì‘ìš©í•˜ê³  ìƒì¡´í•œë‹¤"**

| ë°œí‘œ | ì£¼ì œ | í•µì‹¬ ë©”ì»¤ë‹ˆì¦˜ | ì¹˜ë£Œ íƒ€ê²Ÿ |
|------|------|--------------|----------|
| **Bahn** | C. auris TF networks | Rpn4/Mrr1/Upc2 â†’ Efflux â†‘ | TF inhibitors |
| **Almeida** | Fungal EVs | EV-mediated immune modulation | EV biogenesis ì–µì œ |
| **Lee** | Calcineurin-Byc1 | Amino acid permease regulation | ì§„ê· -íŠ¹ì´ì  Cn inhibitors |
| **Mota** | N-glycan QC | ERQC â†’ EV biogenesis | UGG1 inhibitors |

### í†µí•©ì  ê´€ì 

**ì§„ê·  ë³‘ì›ì„±ì˜ ë‹¤ì¸µ ì‹œìŠ¤í…œ**:
```yaml
Level 1 - ìœ ì „ì ì¡°ì ˆ (Bahn):
  - Transcription factors â†’ Drug resistance
  - Rpn4 = Master regulator (Proteasome + Efflux)

Level 2 - ì„¸í¬ ê°„ í†µì‹  (Almeida):
  - EVs â†’ ì¥ê±°ë¦¬ ì‹ í˜¸ ì „ë‹¬
  - Virulence factors delivery
  - Immune modulation

Level 3 - ì‹ í˜¸ ì „ë‹¬ (Lee):
  - Calcineurin pathway â†’ Stress response
  - Novel target: Byc1 (amino acid permease)

Level 4 - í’ˆì§ˆ ê´€ë¦¬ (Mota):
  - ERQC â†’ Protein homeostasis
  - N-glycan QC â†’ EV biogenesis
```

### ê³µí†µ í…Œë§ˆ: **Redundancy & Robustness**
- ì—¬ëŸ¬ TFê°€ ê°™ì€ efflux pump ì¡°ì ˆ
- Multiple stress response pathways
- EV biogenesisì˜ ì—¬ëŸ¬ ê²½ë¡œ
- â†’ **Single target ì–µì œ = ë¶ˆì¶©ë¶„** â†’ **Combination therapy í•„ìˆ˜**

---

## ğŸ“š ì‚¬ì „ ì½ê¸° (ìš°ì„ ìˆœìœ„)

### í•„ìˆ˜

1. **Yong-Sun Bahn (2025)** - mBio, "Signaling pathways...C. auris"
2. **Fausto Almeida (2025)** - J Extracellular Biology, "EVs from fungal infection"
3. **Catia Mota (2024)** - bioRxiv, "N-glycan QC...EVs"

### ì¶”ì²œ

4. **C. auris Review (2024)** - "Comprehensive Overview of Candida auris"
5. **Calcineurin in fungi (2017)** - Virulence journal

---

## ğŸ¤ Top 5 Questions

1. **[Bahn]** "Rpn4 triple knockout (+ Mrr1 + Upc2) â†’ Pan-azole susceptible? Fitness cost?"
2. **[Almeida]** "C. auris EVs vs. other Candida? Cargo differences?"
3. **[Lee]** "Byc1-PKA mechanistic link? TORC1 involved?"
4. **[Mota]** "UGG1 substrate (no Glc)? ERQC-EV cargo selection?"
5. **[All]** "Combination therapy: Azole + EV biogenesis inhibitor + Calcineurin inhibitor?"

---

## ğŸ¤ ë„¤íŠ¸ì›Œí‚¹ ìš°ì„ ìˆœìœ„

1. **Yong-Sun Bahn** (ì—°ì„¸ëŒ€) â­â­â­ - êµ­ë‚´, C. auris ì „ë¬¸ê°€
2. **Fausto Almeida** (Brazil) â­â­â­ - EV ì„ êµ¬ì
3. **Catia Mota** (KBSI) â­â­ - êµ­ë‚´, N-glycan & EV

---

**ì˜ˆìƒ í•™ìŠµ ì„±ê³¼**:
âœ… C. auris MDR ë©”ì»¤ë‹ˆì¦˜ (TF networks)
âœ… ì§„ê·  EVsì˜ ì—­í•  (ë©´ì—­, virulence, ì§„ë‹¨)
âœ… Calcineurin pathway (ìƒˆë¡œìš´ íƒ€ê²Ÿ Byc1)
âœ… N-glycan QC-EV link (ì§„ê·  íŠ¹ì´ì )
âœ… ì‹ ê·œ í•­ì§„ê· ì œ íƒ€ê²Ÿ 4+

**ì§„ê·  ì—°êµ¬ìì—ê²Œ í•„ìˆ˜ ì„¸ì…˜!** ğŸ„
